7-甲基-1H-吲哚-5-胺 | 90868-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 7-甲基-1H-吲哚-5-胺
• 中文别名: 5-氨基-7-甲基吲哚
• 英文名称: 5-Amino-7-methyl-indol
• 英文别名: 5-amino-7-methylindole；7-methyl-indol-5-ylamine；7-methyl-5-aminoindole；7-Methyl-1H-indol-5-amine
• CAS: 90868-09-0
• 化学式: C₉H₁₀N₂
• mdl: MFCD18427090
• 分子量: 146.192
• InChiKey: MGYKDIVTQIGVNS-UHFFFAOYSA-N

物化性质

• 沸点：
  349.2±22.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-chloro-5-(3,4-dimethoxyphenyl)-3-pyridinecarbonitrile 、 7-甲基-1H-吲哚-5-胺 以 EtOCH₂CH₂OH 为溶剂， 生成 5-(3,4-dimethoxyphenyl)-4-[(7-methyl-1H-indol-5-yl)amino]nicotinonitrile
  参考文献：
  名称：

  Optimization of 5-phenyl-3-pyridinecarbonitriles as PKCθ inhibitors

  摘要：

  The key intermediate, 4-chloro-5-iodo-3-pyridinecarbonitrile, allowed for ready optimization of the PKC theta inhibitory activity of a series of 3-pyridinecarbonitriles. Analog 13b with a 4-methylindol-5-ylamino group at C-4 and a 4-(2-(4-methylpiperazin-1-yl)ethoxy) phenyl group at C-5 had an IC(50) value of 7.4 nM for the inhibition of PKC theta. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.126
• 作为产物：
  描述：

  7-甲基-5-硝基-吲哚 在 钯 氢气 作用下， 以 甲醇 为溶剂， 以yielding an oil (0.16 g, 1.1 mmol, 41%), which的产率得到7-甲基-1H-吲哚-5-胺
  参考文献：
  名称：

  5- and 6-(2-imidazolin-2-ylamino) and

  摘要：

  本发明涉及选择性针对人类α2受体的吲哚和苯并噻唑化合物。本发明还涉及这些化合物的用途，这些用途包括任何需要使用α2激动剂的适应症。具体而言，这包括用作镇痛剂、镇静剂和麻醉剂的用途。此外，本发明还包括使用这些化合物降低眼压、治疗老视、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供一种药物组合物，包括上述定义化合物的治疗有效量和药学上可接受的载体。

  公开号：

  US05677321A1

文献信息

• Substituted 3-cyanopyridines as protein kinase inhibitors
  申请人：Cole Cecil Derek

  公开号：US20070287708A1

  公开（公告）日：2007-12-13

  The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R 1 , R 2 , and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.

  本发明的教导提供了公式I的化合物及其药用可接受的盐、水合物和酯，其中R1、R2和X如本文所述定义。本发明的教导还提供了制造公式I化合物的方法，以及通过向哺乳动物包括人类施用治疗有效量的公式I化合物或化合物来治疗自身免疫性和炎症性疾病的方法。
• 5- and 6-(2-imidazolin-2-ylamino) and
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05677321A1

  公开（公告）日：1997-10-14

  This invention is directed to indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  这项发明涉及选择性作用于克隆人类α2受体的吲哚和苯并噻唑化合物。该发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，该发明包括使用这些化合物降低眼内压、治疗老花眼、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁，以及用作认知增强剂和眼部血管收缩剂。该发明还提供一种包含上述定义化合物的治疗有效量和药用可接受载体的药物组合物。
• Novel indole and benzothiazole derivatives
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：US20020049239A1

  公开（公告）日：2002-04-25

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及新型的吲哚和苯并噻唑化合物，这些化合物对克隆的人类α2受体具有选择性。本发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼内压、治疗老视、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供了一种药物组合物，其中包括上述定义的化合物的治疗有效量和药学可接受的载体。
• Substituted indoles and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06040451A1

  公开（公告）日：2000-03-21

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及一种新型的吲哚和苯并噻唑化合物，其对克隆的人类α2受体具有选择性。本发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼压、治疗老视眼、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞和尿失禁，以及用作认知增强剂和眼部血管收缩剂。本发明还提供一种药物组合物，其中包括上述定义的化合物的治疗有效量和药学上可接受的载体。
• Indole and benzothiazole derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06498177B2

  公开（公告）日：2002-12-24

  This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及新颖的吲哚和苯并噻唑化合物，这些化合物对克隆的人α2受体具有选择性。本发明还涉及这些化合物的用途，用于任何需要使用α2激动剂的适应症。具体来说，包括用作镇痛剂、镇静剂和麻醉剂。此外，本发明还包括使用这些化合物降低眼压、治疗老视、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁以及用作认知增强剂和眼部血管收缩剂。本发明还提供一种药物组合物，包括上述定义的化合物的治疗有效量和药学上可接受的载体。